en
Scientific article
Open access
English

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis

Published inEClinicalMedicine, vol. 28, 100573
Publication date2020-11
First online date2020-10-16
Abstract

Background: To inform World Health Organization (WHO) global guidelines, we updated and expanded the evidence base to assess the comparative efficacy, tolerability, and safety of first-line antiretroviral therapy (ART) regimens.

Methods: We searched Embase, Medline and CENTRAL on 28 February 2020 to update the systematic literature review of clinical trials comparing recommended first-line ART that informed previous WHO guidelines. Outcomes included viral suppression, change in CD4 cell counts, mortality, serious and overall adverse events (AEs), discontinuation, discontinuations due to AEs (DAEs); and new outcomes: drug-resistance, neuropsychiatric AEs, early viral suppression, weight gain and birth outcomes. Comparative effects were assessed through network meta-analyses and certainty in the evidence was assessed using the GRADE framework.

Findings: We identified 156 publications pertaining to 68 trials for the primary population. Relative to efavirenz, dolutegravir had improved odds of viral suppression across all time points (odds ratio [OR]: 1·94; 95% credible interval [CrI]: 1·48-2·56 at 96 weeks); was protective of drug-resistance (OR: 0·13; 95%CrI: 0·04-0·48); and led to fewer discontinuations (OR: 0·58; 95%CrI: 0·48-0·70). Evidence supported dolutegravir use among TB-HIV co-infected persons and pregnant women. Adverse birth outcomes were observed in 33.2% of dolutegravir-managed pregnancies and 35.0% of efavirenz-managed pregnancies. Low-dose efavirenz had comparable efficacy and safety to standard-dose efavirenz, but led to fewer DAEs (OR: 0·70; 95%CrI: 0·50-0·92).

Interpretation: The evidence supports choosing dolutegravir in combination with lamivudine/emtricitabine and tenofovir disoproxil fumarate as the preferred first-line regimen and low-dose efavirenz-based regimens as an alternative. Dolutegravir can be considered to be effective, safe and tolerable.

Funding: WHO.

eng
Keywords
  • Antiretroviral therapy
  • First-line
  • HIV
  • Network meta-analysis
Research group
Funding
  • World Health Organization - [001]
  • NICHD NIH HHS - [K23 HD088230]
Citation (ISO format)
KANTERS, Steve et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. In: EClinicalMedicine, 2020, vol. 28, p. 100573. doi: 10.1016/j.eclinm.2020.100573
Main files (1)
Article (Published version)
Secondary files (2)
Identifiers
ISSN of the journal2589-5370
27views
2downloads

Technical informations

Creation01/30/2023 4:08:03 PM
First validation12/21/2023 5:34:28 PM
Update time12/21/2023 5:34:28 PM
Status update12/21/2023 5:34:28 PM
Last indexation05/06/2024 5:39:23 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack